Veselovska Z.F.
Kyiv Medical University of UAFM, Kyiv, Ukraine
Kyiv City Eye Center, Kyiv City Clinical Hospital no. 1, Kyiv, Ukraine

Summary. The article presents the results of studies on the experience with glaucoma drugs of different pharmacological actions. It was determined that the achievement of low level of the intraocular pressure (IOP) is the necessary component of glaucoma therapy, and in patients with different stages of the disease it is important to reach the necessary level of relative decrease of IOP according to the stage of the primary open-angle glaucoma (POAG). This article includes the data of numerous works that demonstrate the privilege of glaucoma drugs on the base of travoprost, bimatoprost and latanoprost from group of prostaglandin analogues as first-line drugs for the correction of the IOP in patients with newly diagnosed POAG. There is the analysis of treatment strategy with the use of different groups of drugs in the complicated cases with high and bad corrected IOP. The expediency of inclusion in the treatment regime of fixed forms of glaucoma drugs is mainly based on combinations with prostaglandin analogues.

Thus, such approach in the shortest time allows reaching necessary hypo-effect for the stabilization of visual function. The appointment of adequate therapy in severe cases of POAG should be based on the fixed form of combined drugs. Very important is to keep strongly the policy of informing patients about possible side effects of eye drops, learning them with the rules instillation and maintaining the schedule of drops which are very important in lowering for the necessary level of IOP. The patients should be our partner during all process of the therapy of glaucoma.

Keywords: glaucoma, the compensation process, antihypertensive therapy, prostaglandin analogues, travoprost.

REFERENCES
1. Avdeev R. V., Aleksandrov A. S., Bakunina N. A., Basinskiy A. S., Blyum Ye. A., Brezhnev A. Yu., Volkov Ye. N., Gazizova I. R., Galimova A. B., Gaponko O. V., Garkavenko V. V., Getmanova A. M., Gorodnichiy V. V., Gorshkova M. S., Gusarevich A. A., Diordiychuk S. V., Dorofeev D. A., Zhavoronkov S. A., Zavadskiy P. Ch., Zvereva O. G., Karimov U. R., Kulik A. V., Kuroedov A. V., Lanin S. N., Lovpache Dzh. N., Loskutov I. A., Molchanova Ye. V., Ogorodnikova V. Yu., Onufriychuk O. N., Petrov S. Yu., Rozhko Yu. I., Sidenko T. A. On the question of predicting the demonstrations and cost primary open angle glaucoma. Mizhnarodnyi naukovo-praktychnyi zhurnal “Oftalmolohiia” [International scientific-practical journal “Ophthalmology”]. 2015; (1): 27–43 (in Russian).
2. Veselovska N. M., Veselovska Z. F. Fundamental research in ophthalmology – a modern perspective of new approaches to primary and secondary prevention of vascular eye diseases. Mizhnarodnyi naukovo-praktychnyi zhurnal “Oftalmolohiia” [International scientific-practical journal “Ophthalmology”]. 2015; (1): 11–17 (in Ukrainian).
3. Volkov V. V. Proposals to build a modern classification of glaucoma. Vse novosti oftalmologii [All news of ophthalmology]. 2005; (6): 3–4 (in Russian).
4. Gavrilyuk T. I., Danovskaya V. M., Yanenko V. A. The efficacy, tolerability and safety of tafluprost eye drops for glaucoma. Mizhnarodnyi naukovo-praktychnyi zhurnal “Oftalmolohiia” [International scientific-practical journal “Ophthalmology”]. 2015; (1): 68–71 (in Russian).
5. Erychev V. P., Lovpache Dzh. N. The quality of life of patients with glaucoma – the right to choose. Proceedings of the scientific-practical conference “Glaucoma: problems and solutions” (Moscow, November 23–25, 2004). Moscow, 2004, pp. 403–406 (in Russian).
6. Kuroedov A. V. Prospects for the use of combined glaucoma medications (review). Russkiy meditsinskiy zhurnal “Klinicheskaya oftalmologiya” [Russian medical journal “Clinical ophthalmology”]. 2007; (4): 176 (in Russian).
7. South East Asia glaucoma interest group. Asia Pacific glaucoma guidelines. 2004, 92 p.
8. Brandt D., Gross R., Sahl K., Batoosingh A., Liu C., Bossowska I. Bimatoprost/Timolol fixed combination: one-year double-masked, randomized parallel comparison to its individual components in patients with glaucoma or ocular hypertension. In: Book of abstracts World Glaucoma Congress. Singapore, 2007, 174 p.
9. Evciman T., Ozkurt Y. B., Kurna S., Sengor T. A comparison of the fixed combination of Latanoprost and Timolol with the unfixed combination of Latanoprost and Timolol in patients with POAG. In: Book of abstracts 6th Glaucoma symposium. Athens, 2007, 128 p.
10. American Academy of Ophthalmology. Glaucoma. Basic and clinical course. 2005, 242 p.
11. Khairy H. A., Said-Ahmed K. A short-term randomized clinical trial of daily versus alternate day use of travoprost 0.004 % in the treatment of ocular hypertension. Journal of Glaucoma. 2013; (22): 123–126.
12. Holmstrom S., Buchholz P., Walt J., Wickstrøm J., Aagren M. Analytic review of bimatoprost, latanoprost and travoprost in primary open angle glaucoma. Current Medical Research and Opinion. 2005; (21): 1875–1883.
13. Mishra D., Sinha B., Kumar M. Comparing the efficacy of latanoprost (0.005 %), bimatoprost (0.03 %), travoprost (0.004 %), and timolol (0.5 %) in the treatment of primary open angle glaucoma. Korean Journal of Ophthalmology. 2014; (28): 399–407.
14. European Glaucoma Society. Terminology and guidelines for glaucoma. 2015, 88 p.